<table border="0" cellpadding="0" cellspacing="0" width="619" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 9. Bioavailability of Divalproex Sodium Extended-Release Tablets Relative to Divalproex Sodium Delayed-Release Tablets When Divalproex Sodium Extended-Release Tablets Dose is 8 to 20% Higher 
</caption>
<tbody>
<tr>
<th colspan="1">Study Population</th>
<th colspan="1">Regimens</th>
<th colspan="3">Relative Bioavailability</th>
</tr>
<tr>
<th colspan="1">Divalproex Sodium<br/>Extended-Release<br/>Tablets vs.<br/>Divalproex Sodium <br/>Delayed-Release<br/>Tablets </th>
<th colspan="1">AUC<sub>24</sub>
</th>
<th colspan="1">C<sub>max</sub>
</th>
<th colspan="1">C<sub>min</sub>
</th>
</tr>
<tr>
<td> Healthy Volunteers (N=35) <br/>
</td>
<td>1000 &amp; 1500 mg<br/>Divalproex Sodium<br/>Extended-Release<br/>Tablets vs. 875 &amp;<br/>1250 mg Divalproex <br/>Sodium Delayed-Release Tablets <br/>
</td>
<td>1.059<br/>
</td>
<td>0.882<br/>
</td>
<td>1.173<br/>
</td>
</tr>
<tr>
<td> Patients with epilepsy on concomitant enzyme-<br/> inducing antiepilepsy drugs (N=64) <br/>
</td>
<td>1000 to 5000 mg<br/>Divalproex Sodium<br/>Extended-Release<br/>Tablets vs. 875 to<br/>4250 mg Divalproex <br/>Sodium Delayed-Release Tablets <br/>
</td>
<td>1.008<br/>
</td>
<td>0.899<br/>
</td>
<td>1.022<br/>
</td>
</tr>
</tbody>
</table>